Therapies targeting the TIGIT and STING pathways hold therapeutic promise
Safety and efficacy data of some novel immunotherapy agents are encouraging, but more research is needed to identify biomarkers and the optimal treatment schedule
Adoptive cell therapy using TILs shows clinically meaningful and durable efficacy in advanced mucosal melanoma
Antitumour responses were consistent with those previously reported for a broader population of patients with advanced melanoma
An ESMO study reveals that poor quality of real-world data from oncology studies is still an issue
Scarcity of prospective data was reported as well as a limited use of real-world evidence as definitive evidence to regulatory approval decisions of targeted therapies in Europe
Updated hallmarks of cancer guide treatment development
Old and emerging traits of cancer provide a common set of principles that may help research shape future progress
PROs support dostarlimab plus chemotherapy as a new standard of care in endometrial cancer
Data from selected patients in the RUBY trial show improvements in QoL domains over the course of treatment and benefits compared with placebo
Dealing with end-of-life issues in the early stages of an oncologist’s career
Specific training for young oncologists, particularly in managing patient expectations regarding end-of-life treatment, is paramount in providing effective, patient-centred end-of-life care
How can we overcome resistance to immune checkpoint inhibitors in NSCLC?
Results from studies presented at the ESMO Congress 2023 (Madrid, 20–24 October) outline different strategies involving indirect immune modulation and direct enhanced tumour cytotoxicity to improve on chemotherapy as the current standard of second-line care after ICI progression
Checkpoint inhibition improves outcomes in high-risk, locally advanced cervical cancer
In the KEYNOTE-A18 study, the combination of pembrolizumab and concurrent chemoradiotherapy significantly improved progression-free survival
Phase III data confirm that adjuvant radiotherapy has no benefit following radical prostatectomy
Final results from the RADICALS-RT trial show that observation with salvage RT for prostate-specific antigen failure should be the current standard strategy after surgery
Sitravatinib plus nivolumab does not improve survival in NSCLC after immunotherapy and chemotherapy
The SAPPHIRE trial failed to meet its primary endpoint compared with chemotherapy